Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients

Business Wire December 17, 2018

Report: Developing Opportunities within Avangrid, GoDaddy, NGL Energy Partners LP, Lazard, Briggs & Stratton, and Celgene — Future Expectations, Projections Moving into 2019

GlobeNewswire December 10, 2018

The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Benzinga.com  December 4, 2018

Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018

Business Wire December 3, 2018

46 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  December 3, 2018

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

Business Wire December 2, 2018

bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

Business Wire December 2, 2018

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session

Business Wire December 2, 2018

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Business Wire December 2, 2018

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018

Business Wire December 1, 2018

Advancing Clinical Trials Endeavoring to Improve Odds Against Pancreatic Cancer

PR Newswire November 28, 2018

Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma

Business Wire November 27, 2018

The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Benzinga.com  November 15, 2018

Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis

PR Newswire November 14, 2018

Celgene Corporation to Webcast at Upcoming Investor Events

Business Wire November 2, 2018

Results from More Than 100 Abstracts Highlighting Celgene Pipeline Compounds and Therapies to Be Presented at the American Society of Hematology Annual Meeting (ASH)

Business Wire November 1, 2018

The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Benzinga.com  October 26, 2018

The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Benzinga.com  October 25, 2018

Celgene Reports Third Quarter 2018 Operating and Financial Results

Business Wire October 25, 2018

TV Host and Fashion Journalist Louise Roe Shares Her Personal Story With Plaque Psoriasis as Part of INSIDE PERSPECTIVE Campaign

Business Wire October 24, 2018